Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Martirosyan, Anna ^a   Clendening, James W ^a,b   Goard, Carolyn A ^a,b   Penn, Linda Z ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; DOXORUBICIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MEVINOLIN; PROTEIN P53; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; SENSITIZATION; DRUG SCREENING; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COMET ASSAY; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; LOVASTATIN; OVARIAN NEOPLASMS; P-GLYCOPROTEIN;

EID: 77951182123     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-103     Document Type: Article

References (57)

1. Markman M. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci 2008, 29(10):515-519. 10.1016/j.tips.2008.07.007, 18760845.
2. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008, 68(6):771-789. 10.2165/00003495-200868060-00004, 18416585.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
4. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3(7):502-516. 10.1038/nrc1123, 12835670.
5. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC. Focus on epithelial ovarian cancer. Cancer Cell 2004, 5(1):19-24. 10.1016/S1535-6108(04)00002-9, 14749123.
6. Hille S, Rein DT, Riffelmann M, Neumann R, Sartorius J, Pfutzner A, Kurbacher CM, Schondorf T, Breidenbach M. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs 2006, 17(9):1041-1044. 10.1097/01.cad.0000231480.07654.b5, 17001177.
7. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16(4):508-519. 10.1038/sj.leu.2402476, 11960327.
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990, 343(6257):425-430. 10.1038/343425a0, 1967820.
9. Wong WW, Clendening JW, Martirosyan A, Boutros PC, Bros C, Khosravi F, Jurisica I, Stewart AK, Bergsagel PL, Penn LZ. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther 2007, 6(6):1886-1897. 10.1158/1535-7163.MCT-06-0745, 17575117.
10. Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007, 79(3):240-243. 10.1111/j.1600-0609.2007.00902.x, 17655704.
11. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, Estrov Z, Faderl S, Cortes J, Beran M, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 2007, 109(7):2999-3006. 1852228, 17158228.
12. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001, 84(7):886-891. 10.1054/bjoc.2000.1716, 2363838, 11286466.
13. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008, 260(1-2):11-19. 10.1016/j.canlet.2007.11.036, 18180097.
14. Liu H, Liang SL, Kumar S, Weyman CM, Liu W, Zhou A. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol 2008,
15. Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J, Carvajal J, Gejman R, Owen GI, Cuello M. Lipophilic but not hydrophilic statins selectively induce cell death in gynecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med 2009,
16. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004, 64(18):6461-6468. 10.1158/0008-5472.CAN-04-0866, 15374955.
17. Kim SS, Shago M, Kaustov L, Boutros PC, Clendening JW, Sheng Y, Trentin GA, Barsyte-Lovejoy D, Mao DY, Kay R, et al. CUL7 is a novel antiapoptotic oncogene. Cancer Res 2007, 67(20):9616-9622. 10.1158/0008-5472.CAN-07-0644, 17942889.
18. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood 1999, 93(4):1308-1318.
19. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991, 51(13):3602-3609.
20. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004, 104(13):4188-4193. 10.1182/blood-2004-06-2281, 15319277.
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Reg 1984, 22:27-55.
22. Jekerle V, Kassack MU, Reilly RM, Wiese M, Piquette-Miller M. Functional comparison of single- and double-stranded mdr1 antisense oligodeoxynucleotides in human ovarian cancer cell lines. J Pharm Pharm Sci 2005, 8(3):516-527.
23. Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, Barquinero J, Domingo JC, Marin P, Petriz J. Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry A 2004, 62(2):129-138. 10.1002/cyto.a.20072, 15517563.
24. Martirosyan A, Leonard S, Shi X, Griffith B, Gannett P, Strobl J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J Pharmacol Exp Ther 2006, 317(2):546-552. 10.1124/jpet.105.096891, 16497787.
25. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008, 109(3):573-579. 10.1007/s10549-007-9683-8, 17674197.
26. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al. Breast cancer growth prevention by statins. Cancer Res 2006, 66(17):8707-8714. 10.1158/0008-5472.CAN-05-4061, 16951186.
27. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000, 40(1-2):167-178.
28. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, Penn LZ. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001, 7(1):158-167.
29. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 2001, 40(5-6):659-662.
30. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996, 2(3):483-491.
31. Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI. Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000, 57(3):503-511.
32. Meinhold-Heerlein I, Ninci E, Ikenberg H, Brandstetter T, Ihling C, Schwenk I, Straub A, Schmitt B, Bettendorf H, Iggo R, et al. Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 2001, 60(2):176-188. 10.1159/000055316, 11244334.
33. Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002, 16(7):1362-1371. 10.1038/sj.leu.2402501, 12094262.
34. Holmberg M, Sandberg C, Nygren P, Larsson R. Effects of lovastatin on a human myeloma cell line: increased sensitivity of a multidrug-resistant subline that expresses the 170 kDa P-glycoprotein. Anticancer Drugs 1994, 5(5):598-600. 10.1097/00001813-199410000-00012, 7858293.
35. Dimitroulakos J, Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 1996, 2(3):326-333. 10.1038/nm0396-326, 8612233.
36. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A, Ohno R. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000, 14(8):1444-1450. 10.1038/sj.leu.2401856, 10942241.
37. Knox JJ, Siu LL, Chen E, Dimitroulakos J, Kamel-Reid S, Moore MJ, Chin S, Irish J, LaFramboise S, Oza AM. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer 2005, 41(4):523-530. 10.1016/j.ejca.2004.12.013, 15737556.
38. Spek E, Bloem AC, Donk NW, Bogers LH, Griend R, Kramer MH, de Weerdt O, Wittebol S, Lokhorst HM. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006, 91(4):542-545.
39. Spek E, Bloem AC, Sinnige HA, Lokhorst HM. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 2007, 92(12):e130-131. 10.3324/haematol.12071, 18055977.
40. Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008, 111(1):102-105.
41. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008, 14(17):5594-5601. 10.1158/1078-0432.CCR-08-0606, 18765553.
42. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38(7-8):802-832. 10.1080/00498250701867889, 18668431.
43. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001, 132(6):1183-1192. 10.1038/sj.bjp.0703920, 1572659, 11250868.
44. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001, 18(6):800-806. 10.1023/A:1011036428972, 11474784.
45. Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006, 23(3):506-512. 10.1007/s11095-005-9371-5, 16388406.
46. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005, 33(4):537-546. 10.1124/dmd.104.002477, 15616150.
47. Rozados VR, Hinrichsen LI, Binda MM, Gervasoni SI, Matar P, Bonfil RD, Scharovsky OG. Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models. Oncol Rep 2008, 19(5):1205-1211.
48. Riad A, Bien S, Westermann D, Becher PM, Loya K, Landmesser U, Kroemer HK, Schultheiss HP, Tschope C. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res 2009, 69(2):695-699. 10.1158/0008-5472.CAN-08-3076, 19147586.
49. Damrot J, Nubel T, Epe B, Roos WP, Kaina B, Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br J Pharmacol 2006, 149(8):988-997. 10.1038/sj.bjp.0706953, 2014634, 17088865.
50. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80(6):565-581. 10.1016/j.clpt.2006.09.003, 17178259.
51. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001, 19(1):81-83. 10.1023/A:1006481423298, 11291836.
52. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998, 21(6):579-583. 10.1097/00000421-199812000-00010, 9856659.
53. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006, 57(2):155-164. 10.1007/s00280-005-0013-8, 16133537.
54. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, Eckel F, Nader M, Schusdziarra V. Treatment of HCC with pravastatin, octreotide, or gemcitabine--a critical evaluation. Hepatogastroenterology 2004, 51(58):1099-1103.
55. Lopez-Aguilar E, Sepulveda-Vildosola AC, Rivera-Marquez H, Cerecedo-Diaz F, Valdez-Sanchez M, Villasis-Keever MA. Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch Med Res 1999, 30(2):128-131. 10.1016/S0188-0128(98)00018-9, 10372447.
56. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 2009,
57. Lee J, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh do Y, Shin DB, Kim TW, Lee N, et al. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemother Pharmacol 2009, 64(4):657-663. 10.1007/s00280-008-0913-5, 19169686.